Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1431927610093700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Small-area and socially differentiated analyses of the utilization of screening examinations in the city of Hamburg: a secondary data analysis].
Z Evid Fortbild Qual Gesundhwes
January 2025
Institut für Sozialmedizin und Gesundheitssystemforschung, Medizinische Fakultät, Otto-von-Guericke-Universität Magdeburg (Sachsen-Anhalt), Magdeburg, Deutschland.
Introduction: Social reporting in Hamburg identifies existing inequalities at the urban area level. These social-contextual variations may potentially influence preventive health behaviors. The aim of this article is to examine correlations between the degree of social regional disadvantage of Hamburg's population and the utilization of regular screening examinations for children, adolescents, and adults through small-area analysis.
View Article and Find Full Text PDF[Content and quality of web-based health information for the prevention and prediction of food allergies in children: A systematic evaluation].
Z Evid Fortbild Qual Gesundhwes
January 2025
Klinik und Poliklinik für Kinder- und Jugendmedizin der Universität Regensburg, KinderUniKlinik Ostbayern (KUNO), Klinik St. Hedwig, Barmherzige Brüder Regensburg, Regensburg, Deutschland; Wissenschafts- und Entwicklungscampus Regensburg (WECARE), Klinik St. Hedwig, Barmherzige Brüder Regensburg, Regensburg, Deutschland.
Introduction: Web-based health information can support health-related decisions if it is of high quality, i. e. accurate, understandable and barrier-free.
View Article and Find Full Text PDFLong-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.
Front Immunol
January 2025
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
Introduction: Serum levels of interleukin-6 (IL-6) are increased in COVID-19 patients. IL-6 is an effective therapeutic target in inflammatory diseases and tocilizumab, a monoclonal antibody that blocks signaling via the IL-6 receptor (IL-6R), is used to treat patients with severe COVID-19. However, the IL-6R exists in membrane-bound and soluble forms (sIL-6R), and the sIL-6R in combination with soluble glycoprotein 130 (sgp130) forms an IL-6-neutralizing buffer system capable of neutralizing small amounts of IL-6.
View Article and Find Full Text PDF[The 6th Year of the Study of Human Medicine is Mainly Orientated to Practice: a Pilot Study with a Digital Logbook].
Zentralbl Chir
January 2025
Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Magdeburg A. ö. R., Magdeburg, Deutschland.
Digital learning resources are in increasing demand, especially in the light of the planned reform of the medical licensing regulations for 2028. In a pilot project, we digitised and evaluated a logbook for students in their practical year (PJ).The aim of this study is to evaluate the digital and non-digital PJ logbooks.
View Article and Find Full Text PDFRandomised, Placebo-Controlled, Double-Blind Trial to Assess Efficacy and Safety of ELOM-080 in Outpatients with COVID-19.
Adv Ther
January 2025
General Medical Practice, Munich, Germany.
Introduction: Incidences of infections with Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) are still high and treatment guidelines lack specific recommendations for outpatients with Coronavirus-induced disease 2019 (COVID-19). Phytomedicine ELOM-080, an enhancer of mucociliary clearance (MCC), showed benefits as add-on therapy in hospitalised COVID-19 patients.
Methods: This randomised, double-blind, placebo-controlled proof-of-concept study investigated whether outpatients with mild to moderate acute symptomatic COVID-19 would benefit from a 14-day treatment with ELOM-080 with regard to potential early treatment effects on cough and further typical COVID-19 symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!